'Mtor pathway' presentation slideshows

mTOR: a new pathway to target in oncology

206 views • 19 slides

Adjuvant therapy for renal cell carcinoma

Adjuvant therapy for renal cell carcinoma. Dr.Mina Tajvidi oncologist. Surgery. Surgery is curative in the majority of patients without metastatic RCC and is therefore the preferred treatment for patients with stages I, II, and III disease

408 views • 14 slides

Tuberous Sclerosis TSC2

Tuberous Sclerosis TSC2. Morgan von Drehle. Tuberous Sclerosis. Autosomal dominant disorder Sporadic mutations in ~ 2 / 3 cases Occurs in ~1 out of 6,000 individuals Affects organs: brain, heart, kidneys, eyes, skin, lungs Hamartomas Disorder of cell proliferation and migration.

511 views • 14 slides

Merged

A. Vimentin. B. ? -SMA. C. Merged. Figure S1: Representative immunocytochemistry images of cardiac myofibroblasts from adult rats examined by fluorescence microscopy. Vimentin staining (A )with ?-smooth muscle actin (?-SMA) staining (B ). Magnification x40. C: Merged. Col III.

277 views • 6 slides